{
    "clinical_study": {
        "@rank": "47113", 
        "brief_summary": {
            "textblock": "Part 1: To study the potential safety and pharmacokinetic (blood level) effects of\n      zidovudine (AZT) on L-697,661; to obtain additional pharmacokinetic information in humans\n      with L-697,661; to study the effect of L-697,661 on hepatic enzyme induction. Part 2: To\n      begin a study of the antiviral activity of L-697,661.\n\n      L-697,661 is a newly identified compound that inhibits HIV replication (reproduction and\n      growth) in cell culture.  It works together with AZT against HIV."
        }, 
        "brief_title": "A Pharmacokinetic Study of L-697,661 Alone and in Combination With Zidovudine", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "L-697,661 is a newly identified compound that inhibits HIV replication (reproduction and\n      growth) in cell culture.  It works together with AZT against HIV.\n\n      Part 1: Twelve patients are randomly assigned to one of two groups. Group 1 patients receive\n      AZT for 7 days, followed by AZT plus L-697,661 with food for 56 days. Group 2 patients\n      receive no drug for 7 days, followed by L-697,661 with food for 56 days.  Antipyrine is\n      administered 1 hour prior to study drug on days 8, 22, and 35.\n\n      Part 2: Fifteen patients receive L-697,661 with food, for 8 weeks.  Therapy with L-697,661\n      may be extended beyond 8 weeks for up to 24 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  HIV infection.\n\n        Prior Medication: Included:\n\n          -  Patients in Part 1 must have received no previous zidovudine (AZT) or a stable dose\n             of at least 500 mg/day without evidence of toxicity.\n\n          -  Patients in Part 2 must have received no previous AZT or = or > 300 mg/day for < 6\n             consecutive weeks within 1 year prior to study entry.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions or symptoms are excluded:\n\n          -  Acute HIV-related opportunistic infection requiring ongoing treatment.\n\n          -  Diarrhea defined as 3 or more liquid stools/day for one week.\n\n          -  Wilson's or Gilbert's disease, porphyria, or other chronic or acute hepatic disease.\n\n          -  Potentially life-threatening allergic reactions to any of the components of\n             zidovudine.\n\n          -  Acute or chronic medical conditions that in the opinion of the investigator would\n             place patient at risk by participation in this study.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Systemic bronchodilators, acetaminophen, aspirin.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Didanosine (ddI) or dideoxycytidine (ddC) within 14 days prior to entry.\n\n          -  Immune modulators or investigational drugs within 30 days prior to entry.\n\n          -  Drugs known to induce hepatocellular enzymes, such as phenobarbital, phenytoin,\n             warfarin, ketoconazole, and oral contraceptives, within 30 days prior to entry.\n\n        Patients in Part 2 only:\n\n        Excluded:\n\n          -  Zidovudine within 4 weeks prior to receiving first dose of study drug.\n\n        Risk Behavior:\n\n        Excluded:\n\n          -  Patients who the investigator feels would not comply with study requirements.\n\n        Patients may not have the following prior conditions:\n\n          -  Acute or chronic medical conditions that in the opinion of the investigator would\n             place patient at risk by participation in this study.\n\n          -  Potentially life-threatening allergic reactions to any of the components of\n             zidovudine."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "27", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000628", 
            "org_study_id": "ACTG 184", 
            "secondary_id": "Merck Protocol 020-00"
        }, 
        "intervention": [
            {
                "intervention_name": "L-697,661", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Zidovudine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Zidovudine"
        }, 
        "keyword": [
            "Drug Evaluation", 
            "Drugs, Investigational", 
            "Drug Therapy, Combination", 
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex", 
            "Antiviral Agents"
        ], 
        "lastchanged_date": "July 29, 2008", 
        "link": {
            "description": "Click here for more information about Zidovudine", 
            "url": "http://www.aidsinfo.nih.gov/DrugsNew/DrugDetailNT.aspx?MenuItem=Drugs&Search=On&int_id=4"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "941102859"
                    }, 
                    "name": "San Francisco Gen Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80262"
                    }, 
                    "name": "Univ of Colorado Health Ctr / Denver Gen Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Northwestern Univ Med School"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60612"
                    }, 
                    "name": "Rush Presbyterian - Saint Luke's Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "981224304"
                    }, 
                    "name": "Univ of Washington"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Pharmacokinetic Study of L-697,661 Alone and in Combination With Zidovudine", 
        "overall_official": {
            "last_name": "RT Schooley", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Unspecified"
        }, 
        "phase": "Phase 1", 
        "reference": [
            {
                "citation": "Kuritzkes DR, Curtis S, Rosandich M, Stein DS, Schooley RT. Delayed emergence of resistance to L-697,661 in patients receiving concomitant zidovudine. The ACTG 184 Study Team. Int Conf AIDS. 1993 Jun 6-11;9(1):467 (abstract no PO-B26-1994)"
            }, 
            {
                "PMID": "8673545", 
                "citation": "Schooley RT, Campbell TB, Kuritzkes DR, Blaschke T, Stein DS, Rosandich ME, Phair J, Pottage JC, Messari F, Collier A, Kahn J. Phase 1 study of combination therapy with L-697,661 and zidovudine. The ACTG 184 Protocol Team. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Aug 1;12(4):363-70."
            }, 
            {
                "citation": "Campbell TB, Routh JA, Bakhtiari M, Schooley RT, Kuritzkes DR. Detection of genotypic changes in reverse transcriptase during combination therapy with zidovudine and L-697,661. Detection of genotypic changes in reverse transcriptase during combination therapy with zidovudine and L-697,661. Int Conf AIDS. 1993 Jun 6-11;9(1):239 (abstract no PO-A26-0630)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000628"
        }, 
        "source": "National Institute of Allergy and Infectious Diseases (NIAID)", 
        "sponsors": {
            "collaborator": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 1994"
    }, 
    "geocoordinates": {
        "Northwestern Univ Med School": "41.878 -87.63", 
        "Rush Presbyterian - Saint Luke's Med Ctr": "41.878 -87.63", 
        "San Francisco Gen Hosp": "37.775 -122.419", 
        "Univ of Colorado Health Ctr / Denver Gen Hosp": "39.739 -104.985", 
        "Univ of Washington": "47.606 -122.332"
    }
}